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Ewing sarcoma (ES) is a high-grade malignant primary round cell tumour of bone in which there is commonly
extension into extraosseous soft tissues at the time of diagnosis. This report details the clinical, radiological and
pathological features of a case of ES of the tibia in which there was extensive osseous involvement but no
infiltration beyond the periosteum into surrounding soft tissue. We also record the findings of one other ES case
that exhibited similar behaviour. Both cases were male, involved the tibia and had the characteristic t (11;22)
(q24;q12) translocation. No recurrence of tumour or metastasis has been seen in these two cases, both of which
have had 6 years follow-up. Our findings indicate that there is heterogeneity in the behaviour of ES and show that
localized ES is associated with a good prognosis.
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Ewing sarcoma (ES) is a malignant tumour of bone which
is composed of small round tumour cells [1,2]. It accounts
for 6-8% of all primary malignant bone tumours and pre-
dominantly affects children, adolescents and young adults.
It occurs rarely in patients older than 30 years and is more
common in males than females (1.3:1). ES may arise in
any bone. In long bones, the femur and tibia are most
commonly affected [2]. Patients usually present with pain
and swelling but pathological fracture may occur and
some patients exhibit osteomyelitis-like systemic features.
Molecular genetic studies have shown that in over 90% of
cases ES tumour cells exhibit a characteristic reciprocal
chromosomal translocation ie: t(11;22)(q24;q12) which
results in fusion of the EWS gene and the FLI-1 gene [3].
ES is highly aggressive tumour which grows rapidly,
causing extensive destruction of cancellous and cortical
bone. In long bones, the tumour commonly involves the
diaphysis and metaphysis with the epiphysis affected in
only 2% of cases; radiologically, there is extensive per-
meative or moth eaten bone destruction and a soft tissue
mass is seen in approximately 90% of cases at the time
of diagnosis [4]. This report describes in detail a case of
ES in which there was extensive ES involvement of the* Correspondence: nick.athanasou@ndorms.ox.ac.uk
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reproduction in any medium, provided the orshaft and metaphysis of the tibial bone with erosion of
the bone cortex, but unusually no involvement of soft
tissues beyond the periosteum. We also describe the
findings in one other case of ES of the tibia arising in a
male that behaved similarly.Case report
Case 1
A 36-year old male presented with a 5 year history of left
sided shin pain to his general practitioner. A plain radio-
graph taken at the time showed no bone or soft tissue ab-
normality. He presented again a few times with recurrent
left leg and forefoot discomfort, particularly on exercise,
before, 4 years later, complaining of more persistent severe
shin pain, including at night. On clinical examination
there was no bone or soft tissue swelling of the left leg.
There was no other significant medical history and the pa-
tient was otherwise well. Haematological and biochemical
investigations were normal, including white cell count,
ESR and CRP.
Plain radiographs taken at this time showed a large ex-
pansile permeative lytic lesion involving the proximal
half of tumour of the left tibial diaphysis (Figure 1). MRI
demonstrated an intramedullary lesion showing predo-
minantly high signal on the STIR sequence and low sig-
nal on the T1- weighted sequence (Figure 2). The lesion
had a mildly heterogeneous appearance with scattered
areas of ill-defined high signal on the T1 -weightedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Case 1: A) Frontal and B) lateral radiographs of the tibia showing an expansile permeative lytic lesion involving the proximal
tibial diaphysis.
Kashima et al. Clinical Sarcoma Research 2013, 3:2 Page 2 of 6
http://www.clinicalsarcomaresearch.com/content/3/1/2images. The proximal and distal margins of the lesion
were well defined. A small nubbin of tumour measuring
0.5 cm in diameter was seen to extend into the posterior
cortex of the distal third of the lesion. The lesion was
otherwise contained within the bone.
Histopathology of a biopsy of the lesion showed a solid
proliferation of tumour cells with plump cytoplasm and
round vesicular or hyperchromatic nuclei (Figure 2C).
Scattered cells had a vacuolated cytoplasm containing
glycogen. Occasional typical mitotic activity was noted.
The lesion was well-vascularized. The tumour appeared to
infiltrate between bone trabeculae. Immunohistochemistry
showed strong staining of the tumour cells for vimentin
and CD99 (Figure 2D). The tumour cells did not express
cytokeratin, EMA, HMB45, S100, CD45, CD20, CD31,
CD34, Factor 8, podoplanin, muscle/smooth muscle actin,
desmin or NB84a. There was a high proliferating fraction
was noted on KI-67 staining.
Radiological and histological features indicated that
this was an aggressive small round cell tumour that
appeared to be confined to bone. The presence of
glycogen-containing CD99+ cells pointed to a diagnosis
of ES [2]. Molecular genetic investigations to confirm an
EWS rearrangement were attempted on the biopsy ma-
terial but were unsuccessful. Although the results
pointed to a ES-like round cell tumour of bone, the ab-
sence of a soft tissue mass in the face of extensive
intraosseous involvement was thought to be unusual for
this entity. The patient was also noted to be somewhat
outside the typical age range for ES. Staging studies in-
cluding MR of the left lower limb, bone scan and chestCT showed no evidence of metastasis. After discussion
with the patient, a segmental resection of the tibia to in-
clude the lesion and a margin of uninvolved bone was
carried out. Reconstruction of the defect was carried out
with a right vascularised free fibular graft and plating
with stabilization of the left tibia with a 16 hole AO con-
dylar plate and screw fixation.
The resected segment of tibia was grossly expanded and
had a thickened cortex. Cut surface revealed a large hae-
morrhagic tumour 18x4x4cm which filled the medulla of
the tibial shaft and metaphysis (Figure 3A); the tumour
did not appear to extend through the bone cortex. Histo-
logically, there was a solid proliferation of tumour cells
with small round nuclei containing fine chromatin and
scanty clear or eosinophilic cytoplasm. Tumour cells con-
tained glycogen and there was little reticulin formation
within the tumour. The tumour was well- vascularized
and there were focal areas of haemorrhage within the
tumour. There was infiltration of cancellous bone, much
of which was undergoing osteoclastic resorption
(Figure 3B). The tumour extended focally into the bone
cortex reaching the outer surface but not penetrating
through the periosteum into surrounding soft tissue
(Figure 3C). There was no evidence of matrix forma-
tion by tumour cells. Cytogenetic investigation using
interphase FISH revealed the presence of an EWSR1
rearrangement in keeping with a t(11;22)(q24;q12)
translocation.
Taken together, the morphological, immunophenotypic
and molecular genetic findings indicated this was a case
of ES which unusually appeared to be effectively
Figure 2 Case 1: (A) T1-weighted and B) STIR sagittal MRI images showing a mildly heterogeneous, well-defined, expansile
intramedullary lesion that is confined within the bone with the exception of a nubbin of tumour that has breached the posterior
cortex (arrowed). (C) Biopsy histology shows a malignant round cell tumour. (D) Tumour cells strongly express CD99.
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soft tissue involvement. The patient recovered unevent-
fully from the operation. Following surgery he under-
went adjuvant chemotherapy includes six cycles of VIDT
(vincristine, ifosfamide, doxorubicin and toposide). In
addition, he had radiotherapy to the left leg, 45 Gy in 25
fractions with boost to the superior and inferior margins
to 54.5 Gy (9 Gy in 5 fractions). He made a good func-
tional recovery but developed a proximal non-union of
the vascularised fibular graft 18 months after initial sur-
gery, requiring re-excision of the segment of non-union
and refixation with reconstruction using an Ilizarov
frame. He has been regularly followed-up for 6 years and
has shown no evidence of recurrence or development
of metastasis.
Case 2
The above case of ES was widely discussed with pa-
thology, oncology and surgical colleagues, one of whom
(UD) informed us of one other case of ES of the tibia
arising in a 16 year old male that had somewhat similarradiological features with extensive bone but limited soft
tissue involvement. Radiological features of this case are
shown in Figure 4. The biopsy specimen showed a small
round cell tumour which had an EWSR1 rearrangement
consistent with a (11;22) (q 24;q12). The patient was given
neoadjuvant chemotherapy (EURO-E.W.I.N.G. 99). The
tumour regressed and histopathology of the resected
specimen showed extensive necrosis of the tumour that
had extensively involved medullary bone and spread to a
limited extent into overlying deep soft tissue. Six years
post-treatment the patient is in complete remission.
Discussion
The two cases of ES documented in this report are
unusual in that they show extensive tumour involvement
of the tibial bone but limited (Case 2) or no (Case 1)
spread of tumour into surrounding soft tissues. Both
case 1, which was not treated prior to surgical resection,
and case 2, which did receive preoperative chemothe-
rapy, have not shown evidence of recurrence or metasta-
sis after 6 years follow-up; the localized nature of ES in
Figure 3 Case 1: (A) The resected segment of the tibia shows extensive medullary involvement by ES. (B), (C) Histology of the resection
showing ES spread through medullary bone and erosion of the bone cortex.
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extraosseous soft tissue is likely to be significant in re-
gard to this good prognostic outcome.
Most patients with ES present with pain and swelling
of the affected bone and surrounding soft tissues. In case
1, there was no clinical evidence of swelling but bone
pain had been noted several years prior to diagnosis. No
tumour was identified on a plain X-ray when the patient
first complained of bone pain. It was only 4 years laterFigure 4 Case 2: (A) Sagittal image showing a high-signal medullary l
tibia represents reactive oedema. (B) T1-weighted axial image showing intr
component (arrowed).when the patient was again investigated that ES was
identified. Biochemical and haematology investigations
were normal over this 4 year period. Imaging studies
showed a large permeative tumour in which there was
erosion of cortical bone but no evidence of a significant
soft tissue mass or prominent periosteal reaction; the lat-
ter is classically onion skinning in type in ES [1,2]. Case 2
also showed extensive medullary involvement and cortical
disruption with relatively little soft tissue spread.esion of the tibial diaphysis. The linear high signal anterior to the
amedullary tumour with focal cortical erosion and a minor soft tissue
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tures of ES. The tumour cells expressed CD99 and mo-
lecular genetic investigations confirmed an EWSR1
rearrangement. As in most cases of ES, the tumour largely
involved the medulla of the shaft; unusually there was only
focal cortical disruption and the tumour was noted to be
entirely subperiosteal with no involvement of surrounding
soft tissues. No lymphatics are present in bone and this
was confirmed in the present case, where there was no
evidence of podoplanin expression; lymph node metasta-
ses, which can occasionally occur in ES, were not seen in
this case but can occur if there is extension of ES outside
the bone [5].
There are a few reports of relatively low-grade beha-
viour of ES, most of which represent rare examples of
ES where the tumour is localized to bone and exhibits
radiological appearances suggestive of a benign lesion,
such as fibrous dysplasia or a simple cyst of bone [6-8].
In one of these reports [6], a series of fibrous dysplasia-
like ES of the tibia arising in children was described.
Radiologically these cases did not show marked bone de-
struction and there was little or no periosteal reaction or
soft tissue involvement [6]. In case 1 there was permea-
tive lysis of the diaphysis with the proximal and distal
margins of the lesion being well defined. Other cases of
low-grade ES include a benign cystic lesion of the tibial
metaphysis in a 27 year old male [7] and a lytic lesion of
the right humerus in a 24 year old who was initially
diagnosed as osteomyelitis [9]. In most of the above
cases, as in our cases, ES was largely confined to bone
and the prognosis was good.
Several clinical and pathological features have been
shown to have prognostic value in ES [10-13]. In gen-
eral, patients younger than 10 years of age have a better
treatment response and survival rate than older patients.
The tumour site is also thought to be important with
distal extremity disease having a better prognosis.
Tumour volume has been shown to predict survival with
tumours greater than 8 cm in maximum dimension ha-
ving poorer survival. In both case 1 and case 2, the tibia
was affected and tumour volume was relatively high with
much of the bone being affected. A significant feature
likely to have contributed to the favourable outcome in
these cases was that the tumour was effectively confined
to the bone compartment. It has been shown that most
patients with localized resectable ES (involving both
bone and soft tissue) have a relatively good prognosis
following surgery and multiagent chemotherapy, with
five year survival rates of up to 80% [10,13-15]. Localized
disease grossly confined to bone has been reported to
have a five year survival rate of 88% compared to 20%
with extraosseous extension [15]. Whether risk of pro-
gression or relapse associated with non-type 1/non-type
2 EWS-FLI1 fusion is higher than the risk associatedwith other fusion types is controversial, largely due to
the fact that there is a lack of prognostic information on
the value of translocation type in a prospectively col-
lected trial cohort [16]. It is unclear in the cases pre-
sented whether lack of tumour progression is related to
a specific EWS-FLI1 fusion. A number of other biomar-
kers, such as tumour size, which have been related to
poor prognosis in ES, did not appear to correlate with
tumour progression in this case [17].
The previously reported cases of ES developing slowly
over a period of years, taken with the two cases pre-
sented in this report, suggest that there is heterogeneity
in the growth pattern of ES with some tumours exhibit-
ing a relatively long intraosseous phase; several of these
reported cases were in the tibia [6,7]. Early diagnosis is
crucial with regard to disease outcome in ES and other
bone sarcomas. The cases presented in this report show
that identification of localized ES which has not spread
beyond the confines of the bone compartment is import-
ant as it is often associated with a good prognosis.
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